Send to

Choose Destination
Data Brief. 2018 Mar 31;18:1013-1021. doi: 10.1016/j.dib.2018.03.114. eCollection 2018 Jun.

Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches.

Author information

University of Montpellier, LBPC, IRMB, CHU de Montpellier, 34000 Montpellier, France.
Bruker Daltonique, S.A, 34, rue de l'industrie, 67160 Wissembourg, France.
Centre Mémoire Ressources Recherche, CHU Montpellier, hôpital Gui de Chauliac, Université Montpellier I, Montpellier F-34000, France.
Bruker Daltonics Inc., 40 Manning Road, Billerica, MA 01821, USA.
Protein Metrics Inc., 1622 San Carlos Ave., San Carlos, CA 94070 USA.
Bruker Daltonik GmbH, Fahrenheitstrasse 4, 28359 Bremen, Germany.


Top-Down approaches have an extremely high biological relevance, especially when it comes to biomarker discovery, but the necessary pre-fractionation constraints are not easily compatible with the robustness requirements and the size of clinical sample cohorts. We have demonstrated that intact protein profiling studies could be run on UHR-Q-ToF with limited pre-fractionation (Schmit et al., 2017) [1]. The dataset presented herein is an extension of this research. Proteoforms known to play a role in the pathophysiology process of Alzheimer's disease were identified as candidate biomarkers. In this article, mass spectrometry performance of these candidates are demonstrated.


Alzheimer disease; Clinical proteomics; Top-Down label-free proteoform profiling; Ultra-high resolution Q-Tof

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center